Therapeutic Area | MeSH |
---|---|
signs and symptoms pathological conditions | D013568 |
wounds and injuries | D014947 |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Amphadase | hyaluronidase | Amphastar Pharmaceuticals | N-21665 RX | 2004-10-26 | 1 products |
Vitrase | hyaluronidase | Bausch Health Companies | N-21640 RX | 2004-12-02 | 1 products |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Darzalex Faspro | daratumumab and hyaluronidase-fihj | Johnson & Johnson | N-761145 RX | 2020-05-01 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
amphadase | Biologic Licensing Application | 2024-02-01 |
darzalex faspro | Biologic Licensing Application | 2024-08-08 |
herceptin hylecta | Biologic Licensing Application | 2024-11-21 |
hyaluronidase | Biologic Licensing Application | 2021-06-04 |
hylenex recombinant | Biologic Licensing Application | 2024-01-24 |
ocrevus zunovo | Biologic Licensing Application | 2024-11-19 |
opdivo qvantig | Biologic Licensing Application | 2024-12-27 |
phesgo | Biologic Licensing Application | 2024-12-02 |
rituxan hycela | Biologic Licensing Application | 2024-11-20 |
sea clearly hydrating facial spf 35 kinetin | C200263 | 2023-12-05 |
Expiration | Code | ||
---|---|---|---|
efgartigimod alfa / hyaluronidase, Vyvgart Hytrulo, Argenx BV | |||
2030-06-20 | Orphan excl. | ||
daratumumab / hyaluronidase, Darzalex Faspro, Janssen Biotech, Inc. | |||
2028-01-15 | Orphan excl. |
Code | Description |
---|---|
J1575 | Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin |
J3470 | Injection, hyaluronidase, up to 150 units |
J3471 | Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) |
J3472 | Injection, hyaluronidase, ovine, preservative free, per 1000 usp units |
J3473 | Injection, hyaluronidase, recombinant, 1 usp unit |
J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj |
J9311 | Injection, rituximab 10 mg and hyaluronidase |
J9316 | Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg |
J9356 | Injection, trastuzumab, 10 mg and hyaluronidase-oysk |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | 1 | 4 |
Neoplasms | D009369 | — | C80 | — | 2 | — | — | — | 2 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | — | — | 1 |
Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | — | 1 |
Skin neoplasms | D012878 | EFO_0004198 | C44 | — | 1 | — | — | — | 1 |
Melanoma | D008545 | — | — | — | 1 | — | — | — | 1 |
Cutaneous malignant melanoma | D000096142 | — | — | — | 1 | — | — | — | 1 |
Neoplasm micrometastasis | D061206 | — | — | — | 1 | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
Drug common name | Hyaluronidase |
INN | — |
Description | Hyaluronidases are a family of enzymes that catalyse the degradation of hyaluronic acid. Karl Meyer classified these enzymes in 1971, into three distinct groups, a scheme based on the enzyme reaction products. The three main types of hyaluronidases are two classes of eukaryotic endoglycosidase hydrolases and a prokaryotic lyase-type of glycosidase.
|
Classification | Enzyme |
Drug class | enzymes |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | 1FCQ, 1FCU, 1FCV, 1I8Q, 1LOH, 1LXK, 1LXM, 1N7N, 1N7O, 1N7P, 1N7Q, 1N7R, 1OJM, 1OJN, 1OJO, 1OJP, 1W3Y, 2ATM, 2BRP, 2BRV, 2BRW, 2C3F, 2CBI, 2CBJ, 2DP5, 2J1A, 2J1E, 2J62, 2J7M, 2J88, 2JNK, 2OZN, 2PE4, 2WB3, 2WDB, 2WH7, 2YVV, 2YW0, 2YX2, 3EKA, 4D0Q, 4UFQ, 5DIY, 6WV2, 6WWX, 6WXA, 6X3M, 7EYO, 8C6I, 8FNX, 8G0O |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201636 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00070 |
UNII ID | — |